Safety, tolerability and experience

1.png

Clinical trials and extensive real-world experience demonstrated that FLUAD Quad has a systemic safety profile similar to that of other seasonal flu vaccines.1,2

 
 
Untitled-22.png

Vaccination with FLUAD Quad is associated with more local reactions, but a similar level of systemic reactions to other seasonal flu vaccines.

These are usually mild to moderate and typically resolve within 1–3 days.1,3

 
 
Untitled-23.png
 

Approved in New Zealand, Australia, UK, EU, US and other countries.4

186 million doses* have been distributed worldwide.4

 
 

* Dose count includes doses distributed globally as of May 2021 and includes both FLUAD Trivalent and FLUAD Quad.

Reference: 1. Seqirus NZ. FLUAD Quad Data Sheet. Seqirus (NZ) Ltd. November 2022. 2. Frey SE, et al. Vaccine. 2014;32:5027-5034. 3. Beyer WEP et al. Vaccine 29 (2011) 5785– 5792. 4. Data on file. Seqirus Inc; 2021.